ReviewCurrent opinion in rheumatology2013
Cardiovascular disease in lupus: insights and updates.
Review in Current opinion in rheumatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.
- The risks of cancer development in systemic lupus erythematosus (SLE) patients: a systematic review and meta-analysis.Arthritis research & therapy · 2018Pooled it
- Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial.RMD open · 2022Trial
- Safety and Tolerability of Omalizumab: A Randomized Clinical Trial of Humanized Anti-IgE Monoclonal Antibody in Systemic Lupus Erythematosus.Arthritis & rheumatology (Hoboken, N.J.) · 2019Trial
- Malignancies in lupus nephritis: a retrospective cohort study on epidemiology and risk factors.Lupus science & medicine · 2026Article
- Diagnostic implication of left atrial stiffness index in patients with SLE with left ventricular diastolic dysfunction.Lupus science & medicine · 2025Article
- Real-world treatment patterns and clinical characteristics in patients with moderate-to-severe systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS).Lupus science & medicine · 2025Observational
- Identification of immune-related biomarkers linked to systemic lupus erythematosus and dilated cardiomyopathy through integrated bioinformatics analysis and multiple machine learning algorithms.Frontiers in immunology · 2025Article
- An engineered human cardiac tissue model reveals contributions of systemic lupus erythematosus autoantibodies to myocardial injury.Nature cardiovascular research · 2024Article
- An engineered human cardiac tissue model reveals contributions of systemic lupus erythematosus autoantibodies to myocardial injury.bioRxiv : the preprint server for biology · 2024Article
- Exploring the Molecular Mechanisms and Shared Gene Signatures Between Systemic Lupus Erythematosus and Bladder Urothelial Carcinoma.International journal of general medicine · 2024Article
- Assessment of Cardiac Risk in Women with Autoimmune Disease.Current cardiology reports · 2022Review
- Inflammatory bowel disease and atherosclerotic cardiovascular disease in U.S. adults-A population-level analysis in the national health interview survey.American journal of preventive cardiology · 2022Article
- CD8+ T-Cells in Juvenile-Onset SLE: From Pathogenesis to Comorbidities.Frontiers in medicine · 2022Review
- QRISK3-based analysis of cardiovascular risk factors in patients with long-term but well-controlled systemic lupus erythematosus.American journal of translational research · 2022Article
- Understanding Accelerated Atherosclerosis in Systemic Lupus Erythematosus: Toward Better Treatment and Prevention.Inflammation · 2021Review
- Peak strain dispersion within the left ventricle detected by two-dimensional speckle tracking in patients with uncomplicated systemic lupus erythematosus.The international journal of cardiovascular imaging · 2021Article
- Increased apolipoprotein-B:A1 ratio predicts cardiometabolic risk in patients with juvenile onset SLE.EBioMedicine · 2021Article
- Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports.Scientific reports · 2020Article
- Management of cardiovascular disease in patients with systemic lupus erythematosus.Expert opinion on pharmacotherapy · 2020Review
- Cardiogenic shock as the initial manifestation of systemic lupus erythematosus.ESC heart failure · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewWith improved management of the classical disease manifestations of systemic lupus erythematosus (SLE), cardiovascular disease (CVD) has emerged as one of the most important causes of morbidity and mortality. This review in particular focuses on progress over the past year in clinical and basic aspects of SLE-driven accelerated atherosclerosis. RECENT
findingsBoth subclinical CVD and CV events continue to be recognized at increased frequency in previously unstudied lupus cohorts and populations. Novel associations have been identified between lupus CVD and cognitive impairment, depression, and low-income status. In terms of pathogenesis, there is an ever-increasing focus on the innate immune system and, in particular, type I interferons (IFNs). Recent studies have drawn connections in both human and murine models between neutrophils, plasmacytoid dendritic cells, type I IFNs, and endothelial dysfunction. Whether treatments such as mycophenolate mofetil or statins have a role in prevention of lupus CVD is an area of intensive study. SUMMARY: CVD is a major complication of lupus and is now a leading cause of death among people living with this disease. As such, additional studies are needed in order to identify the most effective preventive strategies and most predictive vascular risk biomarkers. Type I IFNs may play a critical role in lupus CVD pathogenesis, and it is recommended that vascular outcomes be included in ongoing trials testing the efficacy of anti-IFN biologics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.